Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer-Reference-Cited by-同舟云学术

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

Published:2017-10 Issue:10 Volume:28 Page:2481-2488
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bellmunt J.,Eigl B.J.,Senkus E.,Loriot Y.,Twardowski P.,Castellano D.,Blais N.,Sridhar S.S.,Sternberg C.N.,Retz M.,Pal S.,Blumenstein B.,Jacobs C.,Stewart P.S.,Petrylak D.P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/10/2481/20232776/mdx400.pdf

Reference22 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence;Millan-Rodriguez;J Urol,2000

3. The treatment of advanced bladder cancer;Sternberg;Ann Oncol,1995

4. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy;Bajorin;J Clin Oncol,1999

5. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer;Herr;J Urol,2001

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small RNAs in Cancer Therapy;Interdisciplinary Cancer Research;2024

2. Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins;Drug Resistance Updates;2022-12

3. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets;International Journal of Molecular Sciences;2022-08-09

4. Revisiting the Old Data of Heat Shock Protein 27 Expression in Squamous Cell Carcinoma: Enigmatic HSP27, More Than Heat Shock;Cells;2022-05-17

5. Heat Shock Proteins and HSF1 in Cancer;Frontiers in Oncology;2022-03-02